For far too many reasons, the term “antibody” has never been more prominent in the public’s eye than it is today. Since SARS-CoV-2 began to hew its way into human history earlier this year, awareness of antibodies and the role they play in human health has hit an all-time high. Type “antibody” into Google Search, and you’ll instantly have access to more than 200 million results.
And while all of us are dealing with the many changes that have come our way, one somewhat positive outcome has been a heightened interest in the benefits of antibody discovery and the researchers who make it happen. In the seven-plus years I’ve worked for Antibody Solutions, I’ve never gotten so many questions from neighbors, friends and people I just happen to meet (in my new virtual life) about my (amazing!) colleagues, the research they conduct and what makes a successful antibody discovery company.
This is one reason I’m especially excited that Antibody Solutions is co-hosting — virtually, of course — the July 30 meeting of Women In Bio-San Francisco. Founded in 2002, Women In Bio is a professional organization dedicated to promoting careers, leadership and entrepreneurship of women in the life sciences. While events are open to all, WIB’s primary mission is to provide women-to-women mentorship and leadership support through all stages of career development.
The topic for this Thursday’s session couldn’t be more timely: “Working Through Adversity, Antibody Discovery and the Pandemic.”
Participation is free, but there are a limited number of spaces available. So please register today and join us for a spirited conversation and network with a community of your peers!
Five industry pros will participate in this exclusive panel discussion that will cover a range of subjects, including the science behind antibodies, how antibodies can be used in research and something with which we’re all familiar: how to navigate the workplace (which, for most of us, is our home) during the pandemic.
Our panel includes:
Judy Lynch-Kenney (moderator) Antibody Solutions
I’m especially excited that Judy Lynch-Kenney, one of my colleagues here at Antibody Solutions and a true pioneer in the Bay Area life science community, will serve as moderator for the meeting. Judy received her Bachelor of Arts in English from the University of South Florida. After moving to California with her husband, Dr. John Kenney, she worked in a number of roles for Syntex Labs Marketing Administration from 1982 to 1995, including positions in the Promotional Materials Department from Inventory Control Specialist to Order Management Supervisor. She co-founded Antibody Solutions with John in 1995 and since then has helped manage the company’s operations and guide its growth over the past 25 years. Judy currently serves as our Chief Financial Officer.
Katherine Harris, PhD Teneobio
Katherine Harris, PhD, works with Teneobio, a multispecific biotherapeutic antibody company that focuses on redirecting the immune system to fight cancer. She joined Teneobio in 2015 and specializes in integrating the use of robotics, lab information systems and bioinformatics to automate processes that enhance efficiency and increase screening capacity. Katherine holds a doctorate in Molecular and Cell Biology from the University of California, Berkeley.
Heather Schwoebel Alloy Therapeutics
Heather Schwoebel leads partnering of platform technologies at Alloy Therapeutics, which offers a royalty-free suite of immunocompetent transgenic mice that enables in vivo human antibody discovery. Heather works to identify opportunities as well as implement and execute strategies to bring Alloy’s suite of platforms and services to all aspects of discovery and translational medicine. She has broad experience in company formation, operations, alliance management and business development with Verseau Therapeutics, Harbour Antibodies & Atlas Venture.
Jennifer Somera Antibody Solutions
Jennifer is a Project Manager at Antibody Solutions, where she works with clients to plan and navigate their antibody discovery programs. For 10 years, she served as a supervisor in the Cell Biology department at Antibody Solutions and helped expand that department and its service offerings. Jennifer has extensive experience in generating and culturing hybridomas, producing monoclonal antibodies, and FACS sorting. She graduated from University of California, Irvine with a Bachelor of Science degree in Biological Sciences.
Vanessa Soros, PhD Tizona Therapeutics
Vaness Soros, PhD, is Director of Antibody Discovery at Tizona Therapeutics, a Bay Area Biotechnology company focused on novel Immuno-Oncology therapeutics. Vanessa leads the team responsible for discovery and developability assessment of therapeutic monoclonal antibodies through cell line development and manufacturing support. Two therapeutic candidates developed under her leadership include TTX-030, a first-in-class anti-CD39 monoclonal antibody to enter clinical trials, and TTX-080 another first-in-class anti-HLAG monoclonal antibody currently entering clinical trials. Before joining Tizona, Vanessa worked as a lead scientist at Catalyst Biosciences and Sea Lane Biotechnologies. Vanessa earned her doctorate in Molecular Biology and Medical Genetics from the University of Toronto and continued her research on the molecular pathology of HIV during her postdoctoral studies at the Gladstone Institute of Virology and Immunology at the University of California, San Francisco.